US-based Merck and Co. and Unnatural Products (UNP) have partnered to collaboratively develop a cancer therapy in a deal amounting to USD 220 million.
Under the partnership, the parties expect to leverage UNP’s drug discovery technology for the development of macrocyclic candidates against an undisclosed oncology therapeutic target.
UNP uses a combination of parallel chemistry and AI-driven techniques to explore the creation of synthetic macrocycles with drug-like properties, akin to naturally occurring evolved macrocycles, which were previously attainable only through injectable antibodies and biologic methods. The company’s AI-based discovery platform is reportedly capable of intelligently designing, rapidly synthesizing, and screening cyclic peptide macrocycles.
As per partnership terms, UNP will receive an undisclosed upfront payment from Merck and be eligible for milestone payments worth up to USD 220 million, based on the candidate’s future development and commercialization.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.